Spectrascience Inc. Provides Revenue Guidance for the Second Quarter Ended June 30, 2012

SpectraScience, Inc. is focused on developing its WavSTAT Optical Biopsy System (WavSTAT). The WavSTAT employs a risk technology that optically illuminates tissue in real-time to distinguish between normal and pre-cancerous or cancerous tissue. The Company has developed a technology platform to determine if tissue is normal, pre-cancerous or cancerous, without the need for a physical biopsy. The WavSTAT4 Optical Biopsy System operates by using cool, safe ultraviolet (UV) laser light to optically illuminate and analyze tissue, enabling the physician to make a diagnosis during endoscopy when screening for cancer and, if warranted, to begin immediate treatment during the same procedure. The WavSTAT4 uses laser-induced auto-fluorescence to obtain spectral information from tissue at the suspected site. The system is classified as a non-significant risk device, which transmits low-level UV laser light energy through an optical fiber to the tissue through the working channel of an endoscope.